Showing results (151-160 of 412) with videos related to
Sort By:
Pageof 42
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.Blood|April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemiaEric Durot, Damien Roos-Weil, Adrien Chauchet, et al.British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequencesJitra Kriangkum, Brian J Taylor, Steven P Treon, et al.Clinical Lymphoma, Myeloma & Leukemia|March 12, 2013
microRNA aberrations in Waldenström macroglobulinemiaAntonio Sacco, Yong Zhang, Patricia Maiso, et al.Journal of the American Academy of Dermatology|December 25, 2019
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse eventsSean Singer, Sally Y Tan, Anna K Dewan, et al.Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.Clinical Lymphoma, Myeloma & Leukemia|July 18, 2025
SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenström MacroglobulinemiaAlberto Guijosa, Alicia de Las Heras, Shayna Sarosiek, et al.Pageof 42